Napazimone for mitochondrial diseases

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 7 Apr 2026: Trial registered, NCT07514338
  2. 12 Jun 2026: Trial started, NCT07514338

The trials

NCT07514338: Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease

State
Under way
Phase
Phase 2
People
140 planned
Started
12 Jun 2026
Primary completion
31 Mar 2029
Arms
Open label extension
Results
None posted
  1. 7 Apr 2026: Trial registered
  2. 12 Jun 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.